GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Cyclically Adjusted PB Ratio

Dynavax Technologies (Dynavax Technologies) Cyclically Adjusted PB Ratio : 3.55 (As of May. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted PB Ratio?

As of today (2024-05-15), Dynavax Technologies's current share price is $11.00. Dynavax Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.10. Dynavax Technologies's Cyclically Adjusted PB Ratio for today is 3.55.

The historical rank and industry rank for Dynavax Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

DVAX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.62   Med: 2.48   Max: 5.38
Current: 3.55

During the past years, Dynavax Technologies's highest Cyclically Adjusted PB Ratio was 5.38. The lowest was 0.62. And the median was 2.48.

DVAX's Cyclically Adjusted PB Ratio is ranked worse than
73.31% of 667 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs DVAX: 3.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Dynavax Technologies's adjusted book value per share data for the three months ended in Mar. 2024 was $4.726. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.10 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dynavax Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted PB Ratio Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 1.19 3.90 3.21 4.37

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 3.91 4.45 4.37 4.00

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted PB Ratio falls into.



Dynavax Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dynavax Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.00/3.1
=3.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynavax Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dynavax Technologies's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.726/129.4194*129.4194
=4.726

Current CPI (Mar. 2024) = 129.4194.

Dynavax Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.731 100.560 7.376
201409 4.624 100.428 5.959
201412 3.820 99.070 4.990
201503 2.595 99.621 3.371
201506 2.465 100.684 3.169
201509 5.496 100.392 7.085
201512 4.866 99.792 6.311
201603 4.271 100.470 5.502
201606 3.605 101.688 4.588
201609 2.810 101.861 3.570
201612 2.311 101.863 2.936
201703 2.143 102.862 2.696
201706 2.567 103.349 3.215
201709 3.374 104.136 4.193
201712 3.243 104.011 4.035
201803 2.665 105.290 3.276
201806 2.097 106.317 2.553
201809 1.547 106.507 1.880
201812 1.003 105.998 1.225
201903 0.664 107.251 0.801
201906 0.163 108.070 0.195
201909 0.467 108.329 0.558
201912 0.099 108.420 0.118
202003 0.135 108.902 0.160
202006 0.532 108.767 0.633
202009 0.629 109.815 0.741
202012 0.533 109.897 0.628
202103 0.871 111.754 1.009
202106 0.727 114.631 0.821
202109 0.564 115.734 0.631
202112 1.809 117.630 1.990
202203 2.276 121.301 2.428
202206 3.344 125.017 3.462
202209 3.924 125.227 4.055
202212 4.553 125.222 4.706
202303 4.388 127.348 4.459
202306 4.482 128.729 4.506
202309 4.682 129.860 4.666
202312 4.803 129.419 4.803
202403 4.726 129.419 4.726

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dynavax Technologies  (NAS:DVAX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dynavax Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (Dynavax Technologies) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Executives
Robert Janssen officer: Chief Medical Officer and VP C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack officer: Senior Vice President 39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess officer: Principal Accounting Officer C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer officer: Co-President and Senior VP C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald officer: SVP and CFO 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman officer: Chief Science Officer and VP C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach officer: VP, CBO, and General Counsel 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063